Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/
The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t
